Protein therapeutic biotech Five Prime Therapeutics Inc. has inked another partnership for its platform with big pharma, this time with Bristol-Myers Squibb Co. to develop and commercialize candidates against a number of checkpoint inhibitor targets. For the biotech, this means an influx of added capital to further internal endeavors, while for Bristol, the deal adds to its immuno-oncology arsenal.
Under the terms of a deal announced March 17, Bristol will pay Five Prime $20 million upfront and $21 million...